Amprius Growth Intact but Execution Risks Remain as NDAA Compliance Looms

What happened

Amprius Technologies is scaling its silicon-anode battery business rapidly, with Q2 revenue up 126% YoY to $34 million and gross margin expanding 1,800 bps to 27%, driven by European drone demand and SiCore batteries accounting for 98% of revenue. Management raised full-year guidance to at least $140 million revenue and at least 28% gross margin, with adjusted EBITDA expected to be at least $4 million, while cash stands at $74.5 million. However, the latest DeepValue report maintains a WAIT rating due to balanced risk/reward: the company must prove outsourced manufacturing yields, manage working capital, and secure NDAA-compliant domestic production targeted for 2027 to unlock U.S. defense demand. Accounts receivable rose to $40.7 million from $23.7 million and inventory to $11.5 million from $6.7 million, raising cash conversion concerns, and insider selling has been notable. The article highlights the attractive end markets beyond drones, but the core thesis hinges on execution and compliance, not just demand.

Implication

The near-term stock reaction may be positive due to the growth narrative, but the DeepValue model suggests limited upside at current price ($11.19) with base case $12 and trim above $16. Given the WAIT rating and conviction 3.0, existing holders should maintain positions but avoid adding unless the stock approaches $9 or Q3 shows clearer cash conversion. The key risks are contract-manufacturing yield issues, NDAA sourcing delays, and receivables growth outpacing revenue, which could trigger a capital raise. Insider selling, particularly by director Sun Kang and CEO Stepien, adds a cautionary signal. Conversely, positive catalysts would be firm order disclosures and stabilization of working capital.

Thesis delta

The article reinforces the demand story, particularly in European drones and future U.S. defense, but does not alter the core thesis that execution and cash conversion are the key risks. The DeepValue report's WAIT rating remains appropriate given the stock is trading near its base-case value with limited margin of safety. The key delta is a slight positive tilt from the article's emphasis on broad end markets, but it does not resolve the working capital and NDAA compliance overhangs.